SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Inflectra

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 2016.
Why 3/10
Inflectra is an already-approved, marketed biosimilar with no pending PDUFA date, pivotal readout, or other binary regulatory catalyst scheduled. The EU marketing authorization was withdrawn in May 2026. As a small part of Pfizer's ~$63B revenue base, even major commercial shifts in this product would not drive a meaningful share-price move for PFE.
Actionable Insight NEUTRAL

Inflectra is a mature, approved biosimilar with no pending regulatory catalysts. The key events to watch are Pfizer's quarterly biosimilar segment revenue trends and any further market-share shifts in the infliximab biosimilar category, but these are gradual commercial developments, not binary stock-moving catalysts for a company of Pfizer's size.

Price Chart

Loading chart...

Executive Summary

Inflectra (infliximab-dyyb) is a biosimilar to Johnson & Johnson's Remicade, approved by the FDA in 2016 as the first biosimilar monoclonal antibody in the US. Developed by South Korea's Celltrion, Pfizer holds exclusive US commercialization rights. The drug treats multiple autoimmune diseases including rheumatoid arthritis, Crohn's disease, and psoriasis. While Inflectra holds about 30% of the US infliximab biosimilar market, it is a mature product with no pending regulatory catalysts. Pfizer has been winding down its Inflectra involvement outside the US: it voluntarily withdrew the EU marketing authorization in May 2026 for commercial reasons, and the product was discontinued in Canada in September 2025 (rebranded as Remdantry by Celltrion). A Class II recall was also initiated in January 2025 for a cGMP deviation. For Pfizer, Inflectra is one of several biosimilars in a portfolio that represents a very small fraction of the company's ~$63 billion annual revenue, making it a negligible stock-moving factor for the stock.

How It Works

Inflectra is a biosimilar version of infliximab (Remicade), a monoclonal antibody that blocks tumor necrosis factor alpha (TNF-alpha), a protein that drives inflammation in autoimmune diseases. By neutralizing TNF-alpha, it reduces inflammation and symptoms in conditions like rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is given as an intravenous infusion.

Trial Status

Inflectra was approved by the FDA on April 5, 2016, based on clinical data demonstrating biosimilarity to Remicade (infliximab). It is a commercially marketed product with no ongoing pivotal trials for the IV formulation. A subcutaneous formulation (Zymfentra) was later approved separately by Celltrion.

The Two-Sided Case

▲ Bull Case4
Inflectra was the first FDA-approved biosimilar monoclonal antibody and remains a well-established infliximab biosimilar with a 30% US market share.
Biosimilars are gaining share in the infliximab market, reaching 51% overall in Q2 2026, with Inflectra holding the largest biosimilar share at 30%.
Pfizer's Q3 2026 results beat estimates and the company raised full-year guidance, with non-COVID products including biosimilars driving growth.
The drug is approved across all eligible indications of the reference product Remicade, covering a broad range of autoimmune diseases.
▼ Bear Case5
Pfizer voluntarily withdrew Inflectra's EU marketing authorization in May 2026 for commercial reasons, shrinking its addressable market.
A Class II FDA recall was initiated in January 2025 after cGMP deviations caused quarantined product to be inadvertently distributed, a manufacturing-quality concern.
Pfizer's biosimilar market share dropped from 16.5% to 13.3% between 2023 and 2024, and the infliximab biosimilar space is increasingly crowded with competitors like Renflexis, Avsola, and Flixabi.
Inflectra is being phased out in Canada (rebranded to Remdantry by Celltrion) and the EU (withdrawn), suggesting Pfizer is de-emphasizing the product outside the US.
Inflectra represents a negligible fraction of Pfizer's ~$63B annual revenue, so even a complete loss of the product would barely move the stock.

Upcoming Catalysts

  • No upcoming PDUFA dates, FDA advisory committee meetings, or pivotal readouts are scheduled for Inflectra. The EU marketing authorization was withdrawn in May 2026. Future developments would be limited to routine commercial updates in Pfizer's quarterly earnings reports.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 10

Hover a chip for the title
1 fda.gov2 pfizer.com3 ema.europa.eu4 bioplayground.com5 ndclist.com6 biosimilarsrr.com7 arthritisnews.jointhealth.org8 pfizer.com9 reportsanddata.com10 alirahealth.com